West Pharmaceutical Services (WST) Non-Current Deferred Tax Liability (2009 - 2026)

West Pharmaceutical Services' Non-Current Deferred Tax Liability history runs 18 years deep, the most recent figure standing at $22.7 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 6.57% year-over-year to $22.7 million; the TTM figure through Mar 2026 stood at $22.7 million (up 6.57% YoY), while the FY2025 annual figure was $23.0 million, down 73.95% from the prior year.
• Non-Current Deferred Tax Liability came in at $22.7 million for Q1 2026 at West Pharmaceutical Services, down from $23.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $88.3 million in Q4 2024 to a low of $1.2 million in Q2 2022.
• A 5-year average of $27.6 million and a median of $16.6 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 1520.41% in 2022 and fell as far as 90.16% in 2022.
• West Pharmaceutical Services' Non-Current Deferred Tax Liability stood at $79.4 million in 2022, then grew by 7.3% to $85.2 million in 2023, then advanced by 3.64% to $88.3 million in 2024, then slumped by 73.95% to $23.0 million in 2025, then declined by 1.3% to $22.7 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $22.7 million, $23.0 million, and $22.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison